Lanza G A, Sestito A, Sandric S, Cioni B, Tamburrini G, Barollo A, Crea F, De Seta F, Meglio M, Bellocci F, Maseri A
Institute of Cardiology, Catholic University of the Sacred Heart, Rome, Italy.
Ital Heart J. 2001 Jan;2(1):25-30.
Spinal cord stimulation (SCS) has been shown to be effective in patients with refractory angina and coronary artery disease. No previous study assessed the clinical effects of SCS in patients with refractory angina who present angiographically normal coronary arteries.
SCS was performed in 7 patients (4 men, 3 women, mean age 59.3 +/- 11 years) with refractory angina and normal coronary arteries. Clinical status was assessed 1 month after SCS device implantation and at a mean follow-up of 11 months (range 2-17 months) by: 1) an estimate of the number of anginal attacks and nitrate consumption in the 2 weeks prior to implantation and to follow-up visits; 2) a score of quality of life by a visual analogic scale; 3) a five-item questionnaire assessing effort angina and satisfaction with treatment; 4) treadmill exercise testing.
At the last follow-up the number of anginal episodes (p < 0.001) and nitrate consumption (p < 0.004) were both reduced by SCS. Visual analogic scale score improved from 2.1 +/- 0.98 to 9.0 +/- 0.9 (p < 0.001) at 1 month and to 6.4 +/- 2.3 (p < 0.01) at the last follow-up. Questionnaire analysis showed that mild (p = 0.006) and moderate (p = 0.000) physical activity, as well as patient satisfaction with anginal status (p = 0.000) and with current treatment (p = 0.000) all improved by SCS. Finally, time to 1 mm ST segment depression, time to angina, and exercise duration were all prolonged by SCS.
Our data point out that SCS may considerably improve anginal symptoms and exercise tolerance in a significant number of patients with refractory angina and normal coronary arteries and therefore it should be considered as a valuable treatment option in this group of patients.
脊髓刺激(SCS)已被证明对难治性心绞痛和冠状动脉疾病患者有效。此前尚无研究评估SCS对冠状动脉造影正常的难治性心绞痛患者的临床效果。
对7例(4例男性,3例女性,平均年龄59.3±11岁)冠状动脉造影正常的难治性心绞痛患者进行了SCS治疗。在SCS装置植入后1个月以及平均随访11个月(范围2 - 17个月)时,通过以下方式评估临床状况:1)估计植入前和随访就诊前2周内心绞痛发作次数和硝酸酯类药物消耗量;2)采用视觉模拟量表评估生活质量得分;3)通过一份五项问卷评估劳力性心绞痛和对治疗的满意度;4)进行平板运动试验。
在最后一次随访时,SCS使心绞痛发作次数(p < 0.001)和硝酸酯类药物消耗量(p < 0.004)均减少。视觉模拟量表得分在1个月时从2.1±0.98提高到9.0±0.9(p < 0.001),在最后一次随访时提高到6.4±2.3(p < 0.01)。问卷分析显示,轻度(p = 0.006)和中度(p = 0.000)体力活动以及患者对心绞痛状况(p = 0.000)和当前治疗(p = 0.000)的满意度均因SCS而改善。最后,SCS使出现1毫米ST段压低的时间、出现心绞痛的时间以及运动持续时间均延长。
我们的数据表明,SCS可显著改善大量冠状动脉造影正常的难治性心绞痛患者的心绞痛症状和运动耐量,因此应将其视为该组患者的一种有价值的治疗选择。